Sensus Healthcare, Inc. (NASDAQ:SRTS) Short Interest Update

Sensus Healthcare, Inc. (NASDAQ:SRTS) was the recipient of a large decline in short interest in the month of February. As of February 28th, there was short interest totalling 845,600 shares, a decline of 28.3% from the February 13th total of 1,180,000 shares. Currently, 6.2% of the shares of the company are sold short. Based on an average daily volume of 325,600 shares, the short-interest ratio is presently 2.6 days.

Analyst Ratings Changes

SRTS has been the subject of several analyst reports. Lake Street Capital decreased their target price on shares of Sensus Healthcare from $18.00 to $13.00 and set a “buy” rating for the company in a research note on Tuesday, March 11th. HC Wainwright boosted their price target on shares of Sensus Healthcare from $11.00 to $12.00 and gave the stock a “buy” rating in a report on Monday, February 10th.

Institutional Investors Weigh In On Sensus Healthcare

A number of large investors have recently modified their holdings of SRTS. JPMorgan Chase & Co. purchased a new stake in shares of Sensus Healthcare during the fourth quarter worth $27,000. Truvestments Capital LLC purchased a new stake in shares of Sensus Healthcare during the third quarter worth $32,000. Barclays PLC purchased a new stake in shares of Sensus Healthcare during the fourth quarter worth $35,000. BNP Paribas Financial Markets purchased a new stake in shares of Sensus Healthcare during the fourth quarter worth $47,000. Finally, IFP Advisors Inc purchased a new stake in shares of Sensus Healthcare during the fourth quarter worth $95,000. Hedge funds and other institutional investors own 25.30% of the company’s stock.

Sensus Healthcare Price Performance

NASDAQ SRTS traded down $0.11 on Tuesday, hitting $4.75. The company had a trading volume of 55,418 shares, compared to its average volume of 307,627. The company has a market capitalization of $78.35 million, a PE ratio of 11.86 and a beta of 1.28. The company’s fifty day moving average price is $5.98 and its 200-day moving average price is $6.64. Sensus Healthcare has a 12-month low of $3.09 and a 12-month high of $9.33.

Sensus Healthcare (NASDAQ:SRTS) last issued its quarterly earnings results on Wednesday, February 5th. The company reported $0.09 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.01). Sensus Healthcare had a return on equity of 12.60% and a net margin of 15.90%. On average, sell-side analysts anticipate that Sensus Healthcare will post 0.32 EPS for the current year.

Sensus Healthcare Company Profile

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.